ClinicalTrials.gg
CompletedNCT06010680Updated Feb 1, 2024

A Study to Evaluate the Mass Balance of [14C]SHR2554 in Healthy Adult Volunteers

A Phase 1 interventional study of [14C]SHR2554 in Lymphoma, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-01.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 275 studies in Lymphoma with a site in China — 102 open to participants now, 118 under way, 10 of them phase 3. Lymphoma · China.

Enrollment
223rd of 232
6 · median 47
Started
2023
with 28 others
Phase 1
83 of 275
25 open now
Registered
200th of 275
by date

Among the 275 studies in Lymphoma with a site in China, this one is the 223rd largest by enrollment of the 232 interventional ones that give a count, is one of 29 that started in 2023, is one of 83 in phase 1, and was the 200th registered.

Lymphoma

3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.

Browse Lymphoma studies →

Open to participants now

102 of the 275 studies in Lymphoma with a site in China are open now. Recruiting first, the newest first:

97 more — sign in →

All 102 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 45 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 275 studies in Lymphoma with a site in China, or all of them as a file.
02

Study summary

Evaluate the Mass Balance of [14C]SHR2554 in Healthy Adult Male Volunteers.

03

Conditions studied

  • Lymphoma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy adult males between 18 and 45 years;
  2. Total Body weight ≥50 kg, and the (BMI) of 19 to 26 kg/m2;
  3. Sign the form prior to the trial and have a full understanding of the trial's procedures, content, and potential adverse reactions;
  4. Ability to communicate effectively with the researchers and comply with the trial requirements.

Exclusion criteria

Exclusion Criteria:

  1. Comprehensive physical examination, vital signs, laboratory tests, 12-lead , chest X-ray (posteroanterior), anal digital examination, abdominal ultrasound with abnormalities as determined by the investigator;
  2. Resting interval (QTcF) >450 ms as obtained from the 12-lead ECG (Note: QTcF interval must be calculated according to Fridericia's method);
  3. Positive results in any of the following tests: surface antigen or hepatitis B e antigen, virus antibodies or antigen/antibody combination test (HIV-Ag/Ab);
  4. Clinically significant abnormalities in ophthalmic examination (slit lamp, intraocular pressure, and fundus photography);
  5. Have taken any clinical trial drug or participated in any clinical trial within 3 months before administration;
  6. inducers or inhibitors were taken within 30 days before administration;
  7. Have taken any prescription or over-the-counter drugs, vitamin products, health care drugs or traditional Chinese medicines within 14 days before administration;
  8. History of any clinically significant medical conditions or conditions that the investigator deems may affect the trial results, including but not limited to cardiovascular, respiratory, endocrine, nervous, digestive, urinary, immune, mental, and metabolic diseases;
  9. History of organic heart disease, congestive heart failure, myocardial infarction, angina pectoris, unexplained history of arrhythmia, history of torsades de pointes, history of ventricular tachycardia, atrioventricular conduction block, history of QT prolongation syndrome, or family history of QT prolongation syndrome (confirmed by genetic testing or sudden cardiac death in a close relative at a young age due to cardiac reasons);
  10. Those who have undergone major surgery within 6 months before administration or that surgical incision has not completely healed; Major surgery includes, but is not limited to, any surgery that is at significant risk of bleeding, prolongs the period of general anesthesia, or has an incision or significant traumatic injury;
  11. Hemorrhoids or anal diseases accompanied by regular/ongoing rectal bleeding; inability to swallow or a history of gastrointestinal dysfunction such as irritable bowel syndrome, inflammatory bowel disease, or previous gastric resection surgery that may affect drug absorption as determined by the investigator;
  12. Allergic predisposition, such as known history of allergy to two or more substances; or deemed by the investigator to be potentially allergic to the drug or its ;
  13. Habitual constipation or diarrhea;
  14. History of alcoholism with alcohol consumption over 14 units per week; and can't abstain from smoking and alcohol during the study;
  15. Heavy smoker or habitually use nicotine-containing products;
  16. Have a history of drug abuse or have used soft drugs (such as: marijuana) within 3 months before administration or take drugs (such as cocaine, amphetamines, phencyclidine, etc.) within 1 year before administration; or positive urine drug abuse test during screening periods;
  17. Habitual consumption of grapefruit juice or excessive tea, coffee and/or caffeinated beverages (more than 8 cups a day, 1 cup = 250 mL) and unable to quit during the study period;
  18. Those who cannot tolerate venipuncture or with a history of needle-sickness and blood-sickness;
  19. Workers who require long-term exposure to radioactive conditions; or those who have significant radiation exposure (≥ 2 chest/abdominal CT scans, or ≥3 other X-ray tests) within 1 year prior to administration or who have participated in radiopharmaceutical labeling tests;
  20. Blood donation no less than 400 mL or have blood transfusion within 3 months of dosing;
  21. Vaccination within one month prior to screening or planning to be vaccinated during the trial;
  22. Intention to conceive or donate sperm during the trial period or within one year after completing the trial, or refusal to strictly adhere to measures by the participant and their spouse/partner from the time of signing the form until one year after completing the trial;
  23. Subjects who, in the opinion of the Investigator should not participate in this study.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    [14C]SHR2554

    Drug: [14C]SHR2554

Interventions

  • Patients will receive single dose of orally \[14C\]SHR2554 on Day 1.

06

What researchers measure

Primary outcomes

  1. Cumulative recovery and recovery rate of total radioactive substance in urine and feces

    Time frame: 0-288 hours

  2. Percentage of parent drug and its metabolites in plasma as a percentage of total radioactive exposure (%AUC)

    Time frame: 0-240 hours

  3. Percentage of parent drug and its metabolites in urine and feces as a percentage of administered dose (%Dose)

    Time frame: 0-288 hours

  4. Radioactivity Tmax

    Time frame: 0-240 hours

  5. Radioactivity Cmax

    Time frame: 0-240 hours

  6. Radioactivity AUC

    Time frame: 0-240 hours

  7. Radioactivity t1/2

    Time frame: 0-240 hours

  8. Radioactivity CL/F

    Time frame: 0-240 hours

  9. Radioactivity Vz/F

    Time frame: 0-240 hours

  10. 1Total radioactivity ratio for blood/plasma

    Time frame: 0-72 hours

Secondary outcomes

  1. Plasma SHR2554: Tmax

    Time frame: 0-240 hours

  2. Plasma SHR2554: Cmax

    Time frame: 0-240 hours

  3. Plasma SHR2554: AUC

    Time frame: 0-240 hours

  4. Plasma SHR2554: t1/2

    Time frame: 0-240 hours

  5. Plasma SHR2554: CL/F

    Time frame: 0-240 hours

  6. Plasma SHR2554: Vz/F

    Time frame: 0-240 hours

  7. Plasma SHR2554: λz

    Time frame: 0-240 hours

  8. AEs and SAEs

    Time frame: 0-12 days

07

Study locations

1 site
  • The First Affiliated Hospital of Suzhou University
    Suzhou, Jiangsu 215008, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2023 to primary completion in Nov 2023, 1 month.

Of 143 industry-sponsored phase 1 interventional studies under Lymphoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 61. This study's 1 month is below that.

Counting every sponsor, half of 281 studies reached it within 53 months; a quarter within 34 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2023
First posted
Aug 24, 2023
StartActual
Oct 7, 2023
Primary completionActual
Nov 27, 2023
CompletionActual
Nov 27, 2023
Last update
Feb 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06010680
Responsible party
Sponsor
First posted
Aug 24, 2023
Start date
Oct 7, 2023
Primary completion
Nov 27, 2023
Completion
Nov 27, 2023
Last update
Feb 1, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zeprumetostat

Start the discussion